Molbio Diagnostics, a prominent player in point-of-care molecular diagnostics headquartered in Goa, has secured regulatory approval from SEBI to launch its much-anticipated initial public offering (IPO), positioning the company for further expansion in India and global markets. The regulator’s clearance, issued in early December 2025, follows the company’s earlier filing of a draft red herring prospectus seeking to raise funds via a fresh equity issue and an offer-for-sale of existing shares.

The IPO structure includes a fresh issue of equity shares worth ₹200 crore alongside an OFS of up to 1.25 crore shares by current investors and shareholders, including institutional backers such as Temasek and Motilal Oswal Private Equity. Proceeds from the fresh issue will be directed toward building advanced R&D infrastructure, establishing a dedicated centre of excellence, and enhancing manufacturing capabilities at its facilities. Management has emphasized that this capital infusion will accelerate innovation in diagnostic products and support higher production volumes for critical testing platforms. 

Founded in 2000, Molbio Diagnostics is best known for its Truenat platform  a portable, battery-operated PCR-based molecular testing system that delivers rapid, accurate results for more than 30 diseases, including tuberculosis, HIV, COVID-19, HPV and hepatitis. The Truenat technology has been widely deployed across public health programmes and resource-limited settings, underscoring the company’s role in expanding access to decentralised diagnostics. With ₹1,020 crore in revenue and ₹138.5 crore in profit for FY25, Molbio enters the public markets amid growing investor interest in healthcare and diagnostics solutions that combine clinical relevance with scalable technology. 

With SEBI’s approval secured, Molbio Diagnostics can now proceed to issue its final red herring prospectus, set the IPO price band and announce subscription dates. The upcoming public listing is widely viewed as a significant development in India’s healthcare capital markets, especially for med-tech and diagnostic companies expanding beyond traditional sectors.